natgillin/translations-raw huggingface dataset:
Effekten af Telzir kan være nedsat på grund af fald i plasmakoncentrationen af amprenavir hos patienter, som tager disse lægemidler (se pkt.
Telzir may be less effective due to decreased amprenavir plasma concentrations in patients taking these medicinal products concomitantly (see section 4.5).
Doseringsanbefalinger for Telzir i kombination med ritonavir
Dosing recommendations for Telzir with ritonavir Age
Medmindre andet er angivet, er studierne nedenfor udført med den anbefalede dosis af fosamprenavir (FPV)/ritonavir (RTV) (dvs. 700/100 mg 2 gange daglig), og interaktionen blev vurderet under steadystate-forhold, efter lægemidlerne var administreret i 10 til 21 dage.
Unless otherwise stated, studies detailed below have been performed with the recommended dosage of fosamprenavir/ritonavir (i.e. 700/100 mg twice daily), and the interaction was assessed under steadystate conditions where drugs were administered for 10 to 21 days.
Fosamprenavir indeholder en sulfonamid.
Fosamprenavir contains a sulphonamide moiety.
Ritonavir AUC12  0,66 Ritonavir Cmax  0,61
Ritonavir AUC12 ↓ 0.66 Ritonavir Cmax ↓ 0.61 Ritonavir C12 ↔ 0.86
Overførelse af amprenavir via placenta har vist sig at forekomme hos mennesker.
Placental transfer of amprenavir has been shown to occur in humans.
(Telzir 1.400 mg 2 gange daglig)
(Telzir 1400 mg twice daily)
Baseline karakteristika ART/PI status, n (%) ART-naive Patienter der tidligere har fået antiretroviral behandling, PI-naive Patienter der tidligere har fået proteasehæmmere, PI-erfarne Median varighed af tidligere ART-eksponering, uger NRTI PI Median plasma hiv-1 RNA log10 kopier/ml
Baseline Characteristics ART/PI status, n (%) ART-naïve ART-experienced, PI-naïve PI-experienced Median duration of prior ART exposure, weeks NRTI PI Median plasma HIV-1 RNA log10 copies/mL
Børn og unge bør tage fosamprenavir oral suspension sammen med mad.
In children and adolescents the fosamprenavir oral suspension should be taken with food.
Samtidig administration af Telzir 700 mg 2 gange daglig og ritonavir i doser større end 100 mg 2 gange daglig er ikke blevet klinisk undersøgt.
Co-administration of Telzir 700 mg twice daily with ritonavir in doses greater than 100 mg twice daily has not been clinically evaluated.
Overordnet kan, selv med ovennævnte dosisjusteringer til voksne med nedsat leverfunktion, nogle patienter have en højere eller lavere amprenavir- og/eller ritonavirkoncentration i plasma end forventet i forhold til patienter med normal leverfunktion pga. øget inter-individuel variation (se pkt.
Overall, even with these dose adjustments for adults with hepatic impairment, some patients may have higher or lower than anticipated amprenavir and/or ritonavir plasma concentrations as compared to patients with normal hepatic function, due to increased inter-patient variability (see section 5.2), therefore close monitoring of safety and virologic response is warranted.
Geometrisk middelændring
Geometric mean change
Fosamprenavir tabletter og oral suspension administreret med ritonavir og kombineret med NRTI'er er blevet evalueret hos proteasehæmmernaive børn og unge, samt hos børn og unge, der tidligere er behandlet med proteasehæmmere.
Fosamprenavir tablets and oral suspension with ritonavir in combination with NRTIs have been evaluated in protease inhibitor naïve and experienced children and adolescent patients.
Læs indlægssedlen inden brug
Oral use Read the package leaflet before use
Lægemidler, som inducerer, hæmmer eller er substrater for CYP3A4, skal derfor bruges med forsigtighed, hvis de skal gives sammen med Telzir og ritonavir (se pkt.
Therefore medicinal products that are inducers, inhibitors or substrates of CYP3A4 must be used with caution when administered concurrently with Telzir with ritonavir (see sections 4.3 and 4.5).
Det frarådes at tage følgende medicin sammen med Telzir/ritonavir:
These medicines are not recommended with Telzir/ritonavir:
APVs geometriske middelværdi (95 % konfidensinterval) og Ctau-værdier var 1,31 (0,97; 1,77), 1,34 (0,95; 1,89) og 2,03 (1,46; 2,83) μg/ml for henholdsvis andet trimester, tredje trimester og post partum og inden for intervallet af værdier hos ikke-gravide patienter på de samme behandlingsregimer med FPV/RTV.
APV geometric mean (95% CI) and Ctau values were 1.31 (0.97, 1.77), 1.34 (0.95, 1.89), and 2.03 (1.46, 2.83) µg/mL for the second trimester, third trimester, and postpartum, respectively and within the range of values in non-pregnant patients on the same FPV/RTV containing regimens.
Derfor kan lægemidler, som har samme metaboliseringsvej eller modificerer aktiviteten af CYP3A4, muligvis ændre farmakokinetikken af amprenavir og ritonavir.
Therefore, any medicinal products that either share this metabolic pathway or modify CYP3A4 activity may modify the pharmacokinetics of amprenavir and ritonavir.
25-O-desacetylrifabutin: AUC(0-48)  11-fold* *sammenlignet med rifabutin 300 mg én gang daglig
25-O-desacetylrifabutin: AUC(0-48) ↑ 11-fold* *compared to rifabutin 300 mg once daily
Påvirkningen af p-ritonavir ved høje systemiske fluticasonkoncentrationer kendes ikke.
The effects of high fluticasone systemic exposure on ritonavir plasma levels are unknown.
Administration af fosamprenavir tabletter efter fødeindtagelse (standardiseret meget fedtholdigt måltid: 967 kcal, 67 gram fedt, 33 gram protein, 58 gram kulhydrat) ændrede ikke på plasma amprenavir farmakokinetikken (Cmax, Tmax eller AUC0-) sammenlignet med administration under faste.
Administration of the fosamprenavir tablet formulation in the fed state (standardised high fat meal: 967 kcal, 67 grams fat, 33 grams protein, 58 grams carbohydrate) did not alter plasma amprenavir pharmacokinetics (Cmax, tmax or AUC0-∞) compared to the administration of this formulation in the fasted state.
Amprenavir metaboliseres hovedsageligt i leveren, og mindre end 1 % udskilles uomdannet i urinen.
Amprenavir is primarily metabolised by the liver with less than 1 % excreted unchanged in the urine.
Administration af fosamprenavir oral suspension sammen med et meget fedtholdigt måltid (967 kcal, 67 gram fedt, 33 gram protein, 58 gram kulhydrat) reducerede plasma amprenavir AUC(0-) med 28 % og Cmax med 46 % og forsinkede Tmax med 0,72 timer.
Administration of the fosamprenavir oral suspension formulation with a high fat meal (967 kcal, 67 grams fat, 33 grams protein, 58 grams carbohydrate) reduced plasma amprenavir AUC(0-∞) by 28% and Cmax by 46% and delayed Tmax by 0.72 hours.
Bivirkningsprofilen var ens i alle de respektive studier med voksne: behandlingsnaive patienter (APV30002, ESS100732) og patienter, der tidligere har været behandlet med proteasehæmmere (dosering 2 gange daglig, APV30003).
The adverse reaction profile was similar across all the respective adult studies: antiretroviral naïve patients (APV30002, ESS100732), protease inhibitor experienced (twice daily dosing, APV30003) patients.
Hvis du får et eller flere af disse symptomer:  Fortæl det til lægen.
If you notice any of these symptoms: →Tell your doctor.
Når antineoplastiske midler, der metaboliseres af CYP3A, administreres samtidigt med fosamprenavir/ritonavir, kan plasmakoncentrationerne af disse antineoplastiske lægemidler øges og kunne øge risikoen for bivirkninger, der normalt er forbundet med disse antineoplastiske midler.
When antineoplastic agents that are metabolised by CYP3A are co-administered with fosamprenavir/ritonavir, plasma concentrations of these antineoplastic medications may be increased and could increase the risk of adverse events usually associated with these antineoplastic agents.
Telzir 700 mg filmovertrukne tabletter Fosamprenavir
Telzir 700 mg film-coated tablets Fosamprenavir
Kan resultere i en øget risiko for PDE5-hæmmerassocierede bivirkninger, herunder hypotension, synsændringer og priapisme (se produktinformationen for PDE5hæmmer).
It may result in an increase in PDE5 inhibitor-associated adverse reactions, including hypotension, visual changes and priapism (refer to PDE5 inhibitor prescribing information).
Kan forårsage alvorlige bivirkninger (se pkt.
It may cause serious adverse reactions (see section 4.4).
Ketoconazol 200 mg en gang daglig i 4 dage
Ketoconazole 200 mg once daily for four days
Ketoconazol: Cmax  25 % Ketoconazol: AUC  2,69 fold.
Ketoconazole: Cmax ↑ 25% Ketoconazole: AUC ↑ 2.69fold.
Ingen FPV/RTV interaktionsstudier dasatinib:  forventet nilotinib:  forventet ibrutinib:  forventet vinblastin:  forventet everolimus:  forventet (CYP3A4 hæmning)
No FPV/RTV drug interaction studies dasatinib: ↑ expected nilotinib: ↑ expected ibrutinib: ↑ expected vinblastine: ↑ expected everolimus: ↑ expected (CYP3A4 inhibition)
Alle patienter i dette studie havde tidligere oplevet behandlingssvigt på et proteasehæmmerregime (defineret som plasma hiv-1-RNA som aldrig kom under 1.000 kopier/ml efter mindst 12 konsekutive ugers behandling, eller som initial suppression af hiv-1-RNA med efterfølgende rebound til  1.000 kopier/ml).
All patients in this study had failed treatment with a previous protease inhibitor regimen (defined as plasma HIV-1 RNA that never went below 1,000 copies/ml after at least 12 consecutive weeks of therapy, or initial suppression of HIV-1 RNA which subsequently rebounded to ≥ 1,000 copies/ml).
Samtidig administration af Telzir og simvastatin eller lovastatin er kontraindiceret pga. øgede plasmakoncentrationer af simvastatin og lovastatin, hvilket kan øge risikoen for myopati, herunder rabdomyolyse (se pkt.
Concomitant use of Telzir with simvastatin or lovastatin is contraindicated because of increased plasma concentrations of lovastatin and simvastatin which can increase the risk of myopathy, including rhabdomyolysis (see section 4.5).
Alvorlige proteasemutationer opstået under behandling eller APV-forbundet blev set i virus isoleret fra 2 patienter.
Treatment-emergent major or APV-associated protease mutations were observed in virus isolated from 2 patients.
> 100.000 kopier/ml
>100,000 copies/ml, n (%)
Signifikant nedsat amprenavir Cmin er observeret, hvilket kan medføre virologisk svigt hos nogle patienter.
Significant reductions in amprenavir Cmin observed may result in virological failure in patients.
Børn kan tage voksendosis af ritonavir kapsler (100 mg 2 gange daglig), hvis de vejer mindst 33 kg og kan sluge kapslerne hele.
Children can take the adult dose of ritonavir capsules (100 mg twice daily) if they weigh at least 33 kg and can swallow the capsules whole.
Lægen vil afgøre, om medicinen kan tages sammen med Telzir og ritonavir.
Your doctor will decide if these medicines are suitable for you to take with Telzir and ritonavir.
Autoimmune sygdomme (som f.eks. Graves´ sygdom og autoimmun hepatitis) er også blevet rapporteret i forbindelse med immunreaktivering; dog er den rapporterede tid til frembrud mere variabel, og frembrud kan forekomme mange måneder efter behandlingsstart (se pkt.
Autoimmune disorders (such as Graves' disease) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Lovastatin:  forventet
Lovastatin: ↑ expected Simvastatin: ↑ expected
Mekanismen for denne interaktion er CYP3A4hæmning af fosamprenavir/ritonavir.
mechanism of interaction is CYP3A4 inhibition by fosamprenavir/ritonavir.
Telzir i kombination med en lav dosis ritonavir er indiceret til behandling af hiv-1-inficerede voksne, unge og børn over 6 år i kombination med andre antiretrovirale lægemidler.
Telzir in combination with low dose ritonavir is indicated for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adults, adolescents and children of 6 years and above in combination with other antiretroviral medicinal products.
CD4-celletal < 50
All Patients CD4-count <50
En 10 ml doseringssprøjte og en adapter er vedlagt i pakningen
A 10 ml graduated dosing syringe and an adapter are also included in the pack.
Produktresumeet for ritonavir skal derfor læses før påbegyndelse af behandlingen med Telzir.
The Summary of Product Characteristics of ritonavir must therefore be consulted prior to initiation of therapy with Telzir.
Lægen vil måle dit blodsukker, inden du begynder behandling med Telzir og løbende, mens du er i behandling.
Your doctor will monitor your blood glucose levels before and during treatment with Telzir.
ALFA1-ANTAGONISTER Alfuzosin
ADRENORECEPTOR ANTAGONIST Alfuzosin,
700 mg (1 tablet eller 14 ml suspension)
Tablet or Oral suspension 700 mg (1 tablet or 14 ml suspension)
(RTV inducerer og/eller hæmmer CYP2C9)
(Induction and/or inhibition of CYP2C9 by RTV)
Børn, som vejer mindre end 39 kg, bør anvende Telzir oral suspension, idet den nøjagtige dosering til denne patientgruppe baseres på kropsvægt (se i produktresuméet for Telzir oral suspension).
For children weighing less than 39 kg, Telzir oral suspension is the recommended option for the most accurate dosing in children based on body weight (please refer to the Summary of Product Characteristics for Telzir oral suspension).
Terapeutiske koncentrationsmålinger anbefales for immunosuppresive lægemidler (cyclosporin, tacrolimus, rapamycin), når disse administreres samtidig med Telzir (se pkt.
Therapeutic concentration monitoring is recommended for immunosuppressant medicinal products (cyclosporine, tacrolimus, rapamycin) when co-administered with Telzir (see section 4.5).
Fortæl altid lægen eller apotekspersonalet, hvis du bruger anden medicin eller har gjort det for nylig.
Tell your doctor or pharmacist if you're taking or have recently taken any other medicinesthese include herbal medicines or other medicines you bought without a prescription.
Der er ikke foretaget studier af virkninger på evnen til at føre motorkøretøj eller betjene maskiner for Telzir i kombination med ritonavir.
No studies on the effects of Telzir in combination with ritonavir on the ability to drive and use machines have been performed.
• maraviroc (mod hiv-infektion).
• maraviroc (used to treat HIV infection)
AAUCMB gennemsnitlig forskel (97,5 % CI)
AAUCMB Mean Diff (97.5% CI)
• ændringer i kropsfacon
• Change in your body shape
APV29005 involverede 30 patienter mellem 6 og 11 år (hvoraf de fleste blev behandlet med 18 mg fosamprenavir/kg og 3 mg ritonavir/kg 2 gange daglig eller voksendoseringen) og 40 patienter mellem 12 og 18 år (hvoraf de fleste blev behandlet med voksendoseringen).
APV29005 enrolled 30 patients aged 6 to 11 (the majority of whom were treated with fosamprenavir / ritonavir 18/3 mg/kg twice daily or the adult tablet regimen) and 40 patients aged 12 to 18 (the majority of whom were treated with the adult tablet regimen).
Denne anvendes til patienter, som ikke kan synke tabletter, og til pædiatriske patienter, som vejer under 39 kg (se i produktresuméet for Telzir oral suspension).
Telzir is also available as an oral suspension for use in patients unable to swallow tablets, and in paediatric patients less than 39 kg (please refer to the Summary of Product Characteristics for Telzir oral suspension).
Når fosamprenavir og ritonavir administreres samtidig vil ritonavirs metaboliske interaktion tilsyneladende dominere, idet ritonavir er en mere potent CYP3A4-hæmmer.
When fosamprenavir and ritonavir are co-administered, the ritonavir metabolic drug interaction profile may predominate because ritonavir is a more potent CYP3A4 inhibitor.
Hvis du ammer eller planlægger at amme:  Tal straks med lægen.
If you are breast-feeding, or thinking about breast-feeding: →Talk to your doctor immediately.
Naturprodukter indeholdende perikon (Hypericum perforatum) må ikke anvendes samtidig med Telzir på grund af risiko for fald i plasmakoncentrationen og risiko for reduceret klinisk effekt af fosamprenavir (se pkt.
Herbal preparations containing St John's wort (Hypericum perforatum) must not be used while taking Telzir due to the risk of decreased plasma concentrations and reduced clinical effects of amprenavir (see section 4.5).
Fænotype-resistens-test
Phenotypic resistance testing
Cmax 56 % (-70 % til -34 %) AUC 54 % (-66 % til -37 %) Cmin 54 % (-74 % til -18 %)
Cmax ↓ 56% (-70%; -34%) AUC ↓ 54% (-66%; -37%) Cmin ↓ 54 % (-74%; -18%)
Som en generel regel bør data fra dyrestudier såvel som klinisk erfaring fra gravide medtages i overvejelserne i beslutningen om, hvorvidt antiretrovirale lægemidler skal anvendes i behandlingen af hiv-infektion hos gravide for at nedsætte risikoen for vertikal transmission af hiv til den nyfødte.
As a general rule, when deciding to use antiretroviral agents for the treatment of HIV infection in pregnant women and consequently for reducing the risk of HIV vertical transmission to the newborn, the animal data (see section 5.3) as well as the clinical experience in pregnant women should be taken into account.
Ved samtidig behandling af hepatitis B eller C med antivirale midler henvises til produktresumeet for disse lægemidler.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products.
• sildenafil, vardenafil eller tadalafil (mod impotens)
• sildenafil, vardenafil or tadalafil (used to treat erectile dysfunction)
Lægemidler - interaktioner Brugen af Telzir sammen med halofantrin eller lidocain (systemisk) kan ikke anbefales.
The use of Telzir concomitantly with halofantrine or lidocaine (systemic) is not recommended.
Lægemiddelrelaterede bivirkninger var mere almindelige i APV20003 (57 %), hvor patienterne fik behandling med fosamprenavir/ritonavir en gang daglig sammenlignet med APV29005 (33 %), hvor patienterne fik fosamprenavir/ritonavir 2 gange daglig.
Drug-related adverse reactions were more common in APV20003 (57%) where subjects received once daily fosamprenavir / ritonavir when compared to APV29005 (33%) where subjects received twice daily fosamprenavir / ritonavir.
Tricykliske antidepressiva:  forventet
Tricyclic antidepressant: ↑ expected
Både fosamprenavirs aktive metabolit, amprenavir, og ritonavir metaboliseres i leveren af CYP3A4.
Additionally, both amprenavir, the active metabolite of fosamprenavir, and ritonavir are primarily metabolised in the liver by CYP3A4.
Kassér den orale suspension 28 dage efter første åbning af flasken
EXP Discard 28 days after first opening
Dette lægemiddel indeholder konserveringsmidler: Methylparahydroxybenzoat (E218) og propylparahydroxybenzoat (E216), se indlægssedlen for flere oplysninger
This product also contains preservatives: methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216), see leaflet for further information
Forsøg på at modvirke denne reduktion i amprenavir-AUC, ved at øge dosis af andre proteasehæmmere sammen med ritonavir, resulterede i en højere forekomst af leverpåvirkninger.
During attempts to overcome the decreased exposure by increasing the dose of other protease inhibitors with ritonavir, a high frequency of liver reactions was seen.
Kassér den orale suspension 28 dage efter første åbning af flasken.
Discard 28 days after first opening.
Lægen kan nedsætte dosis af Telzir og ritonavir i forhold til din leverfunktion.
Your doctor may lower your dose of Telzir and ritonavir depending on the amount of liver damage.
Metaboliske parameter: Kropsvægt og niveauerne af lipid og glucose i blodet kan stige under antiretroviral behandling (se pkt.
Metabolic parameters: weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4).
Det er vigtigt, at du tager hele dagens dosis af både Telzir og ritonavir.
It is very important that you take the full daily dose of Telzir and ritonavir as prescribed by your doctor.
Calciumchloriddihydrat Syntetisk grape-tyggegummismagsstof Naturligt pebermyntesmagsstof Renset vand
Calcium chloride dihydrate Artificial grape bubblegum flavour Natural peppermint flavour Purified water
Den forventede eksponering er baseret på ekstrapolation af data efter administration af fosamprenavir 300 mg 2 gange daglig med ritonavir 100 mg én gang daglig hos personer med moderat nedsat leverfunktion.
Predicted exposures are based on extrapolation from data observed following administration of fosamprenavir 300 mg twice daily with ritonavir 100 mg once daily in subjects with moderate hepatic impairment.
Løs afføring, kvalme, opkastning, mavesmerter
Loose stools, nausea, vomiting, abdominal pain
Telzir i kombination med ritonavir bør anvendes med forsigtighed og i reducerede doser til voksne med let, moderat eller svært nedsat leverfunktion (se pkt.
Telzir with ritonavir should be used with caution and at reduced doses in adults with mild, moderate or severe hepatic impairment (see section 4.2).
Hvis du tager Telzir og ritonavir samtidig med p-piller, kan det skade din lever og nedsætte virkningen af p-pillerne.
Taking Telzir and ritonavir while taking the contraceptive pill may harm your liver and may stop the contraceptive from working properly.
Samtidig administration af Telzir og ritonavir må ikke kombineres med lægemidler, som har smalt terapeutisk vindue og som i høj grad er afhængig af CYP2D6 metabolisme, f.eks. flecainid og propafenon (se pkt.
Telzir with ritonavir must not be co-administered with medicinal products with narrow therapeutic windows that are highly dependent on CYP2D6 metabolism, e.g. flecainide and propafenone (see section 4.5).
Effekten og bivirkningerne af tricykliske antidepressiva skal omhyggelig overvåges (se pkt.
Careful monitoring of the therapeutic and adverse reactions of tricyclic antidepressants is recommended (see section
Den primære elimineringsvej for amprenavir og ritonavir er via leveren.
The principal route of amprenavir and ritonavir elimination is hepatic metabolism.
Børn og unge over 6 år
Children and adolescent patients above the age of six
Telzir bør seponeres permanent i tilfælde af sværere udslæt eller i tilfælde af moderat udslæt ledsaget af systemiske eller mucosale symptomer (se pkt.
Telzir should be permanently discontinued in case of severe rash, or in case of rash of moderate intensity with systemic or mucosal symptoms (see section 4.8).
Hvis en patient allerede tager perikon, skal niveauet for amprenavir, ritonavir og hiv-RNA tjekkes og perikon seponeres.
If a patient is already taking St John's wort, check amprenavir, ritonavir and HIV RNA and stop St John's wort.
Farmakokinetikken for fosamprenavir er ikke undersøgt hos patienter over 65 år (se pkt.
The pharmacokinetics of fosamprenavir have not been studied in this patient population (see section 5.2).
Hos hanrotter sås en højere forekomst af interstitiel celle-hyperplasi ved eksponeringsniveauer 0,5 gange større end den humane, og i hunrotter sås en stigning i uterin endometrial adenocarcinomaer ved eksponeringsniveauer 1,1 gange større end den humane.
In rats only there was an increase in interstitial cell hyperplasia in males at exposure levels equivalent to 0.5-fold those in humans, and an increase in uterine endometrial adenocarcinoma in females at an exposure level equivalent to 1.1-fold those in humans.
Telzir må ikke administreres samtidig med lægemidler, som har et smalt terapeutisk vindue, og som er substrater for CYP3A4, f.eks. alfuzosin, amiodaron, astemizol, bepridil, cisaprid, dihydroergotamin, ergotamin, pimozid, quetiapin, quinidin, terfenadin, oral midazolam (se pkt.
Telzir must not be administered concurrently with medicinal products with narrow therapeutic windows that are substrates of cytochrome P450 3A4 (CYP3A4), e.g. alfuzosin, amiodarone, astemizole, bepridil, cisapride, dihydroergotamine, ergotamine, pimozide, quetiapine, quinidine, terfenadine, oral midazolam (for caution on parenterally administered midazolam, see section 4.5), oral triazolam, sildenafil used for the treatment of pulmonary arterial hypertension (for use of sildenafil in patients with erectile dysfunction, see sections 4.4 and 4.5).
Den anbefalede dosis er 0,36 ml/kg Telzir oral suspension (18 mg pr. kg fosamprenavir) 2 gange daglig sammen med 3 mg/kg ritonavir oral opløsning 2 gange daglig.
The recommended dose is 0.36 ml/kg of Telzir oral suspension (18 mg per kg fosamprenavir) twice daily with 3 mg/kg ritonavir oral solution twice daily.